Skip to content

The Biology and Diagnosis of MPS IV

Last updated:

MPS IV (Morquio Syndrome) is a genetic condition caused by GALNS or GLB1 gene mutations, leading to a missing enzyme and a buildup of keratan sulfate. Diagnosis requires a urine screening, an enzyme activity test, and genetic sequencing to confirm the exact mutations.

Key Takeaways

  • MPS IV is caused by mutations in either the GALNS gene (Type A) or the GLB1 gene (Type B).
  • The condition follows an autosomal recessive inheritance pattern, meaning both parents are usually asymptomatic carriers.
  • A complete diagnosis requires urine GAG screening, an enzyme activity assay, and molecular genetic testing.
  • Higher levels of residual enzyme activity are sometimes associated with a milder form of the condition.
  • Consulting a genetic counselor is recommended to interpret complex lab results and understand family recurrence risks.

Understanding how Morquio Syndrome (MPS IV) works at a biological level can help you make sense of the complex lab reports and genetic results you receive. At its core, this condition is a breakdown in the body’s recycling system, caused by tiny changes in the genetic code [1].

The Biology of the “Build-up”

In a healthy body, specific enzymes (special proteins) act like scissors to break down complex sugars called glycosaminoglycans (GAGs) [1]. In Morquio Syndrome, these “scissors” are either missing or don’t work correctly because of a mutation in the DNA [2].

  • MPS IVA (Type A): A mutation in the GALNS gene leads to a deficiency of the GALNS enzyme [2][1].
  • MPS IVB (Type B): A mutation in the GLB1 gene leads to a deficiency of the beta-galactosidase enzyme [1].

When these enzymes are deficient, a specific GAG called keratan sulfate begins to accumulate in the body’s tissues [2][3]. This buildup is particularly hard on the skeletal system—affecting bone growth and joint stability—which is why the most visible signs are often related to height and mobility [1][3].

How It Is Inherited and Passed On

Morquio Syndrome follows an autosomal recessive inheritance pattern [1]. This means it is not caused by anything a parent did or didn’t do; rather, it is a matter of genetic chance [4].

  • For Parents: Both biological parents of a child with Morquio are typically carriers [1]. They each have one working gene and one mutated gene. Carriers do not have any symptoms of the disease. When two carriers have a child, there is a 25% chance in each pregnancy that the child will inherit the mutated gene from both parents and have Morquio Syndrome [5][6].
  • Testing Siblings: Biological siblings of an affected child can be tested to see if they are carriers or asymptomatically affected themselves [4].
  • For Patients Planning a Family: If you have MPS IV, all of your future children will automatically inherit one mutated gene from you, making them at least carriers. Their risk of actually having the disease depends entirely on whether your partner is also a carrier [5].

The Diagnostic Journey

Confirming a diagnosis usually involves a three-step process to ensure accuracy:

  1. Urine GAG Screening: Doctors check for elevated levels of keratan sulfate in the urine [3]. While this is a common first step, it is not definitive because GAG levels naturally drop with age, which can lead to “false negatives” [3][7].
  2. Enzyme Activity Assay: This is often considered the definitive biochemical test [3]. Scientists measure the activity of the GALNS or GLB1 enzyme in white blood cells (leukocytes) or skin cells (fibroblasts) [3]. If the activity is very low (often near zero), it confirms the deficiency [8].
  3. Molecular Genetic Testing: The final confirmation comes from “sequencing” the gene (GALNS or GLB1) to find the exact mutations [3][9]. This identifies the specific genetic mistakes causing the enzyme deficiency [9].

Deciphering the Lab Report

When looking at a genetic or enzyme report, you may see several technical terms:

  • Residual Activity: This refers to the small amount of enzyme function that may still exist [8]. Higher levels of residual activity are sometimes associated with a “milder” or “attenuated” form of the condition [8][10].
  • Pathogenic Variant: This is a mutation that is known to cause the disease [8][11].
  • Variant of Uncertain Significance (VUS): This means a genetic change was found, but scientists aren’t sure yet if it’s harmful or just a normal variation [12][11]. If a VUS is present, the doctor may need to do more research or tests to see if it explains the symptoms [12][13].
  • Biallelic: This means that two mutations were found—one on each copy of the gene [9].

Auditing the Diagnosis for Completeness

To ensure a complete and accurate diagnosis, check that the medical file includes:

  • [ ] A report identifying which specific gene is affected (GALNS or GLB1) [1].
  • [ ] Verification of two mutations (biallelic), which is standard for recessive conditions [9].
  • [ ] An enzyme test result that shows a clear deficiency matching the genetic findings [3].
  • [ ] A review of the findings by a genetic counselor to explain the recurrence risk for family members [4][14].

Frequently Asked Questions

How is Morquio Syndrome (MPS IV) inherited?
Morquio Syndrome is an autosomal recessive condition, meaning a child inherits one mutated gene from each parent. The parents are usually healthy carriers, and there is a 25 percent chance with each pregnancy that their child will have the condition.
What tests are used to diagnose MPS IV?
Diagnosis typically involves a three-step process: a urine test to check for high levels of keratan sulfate, an enzyme activity assay to confirm the enzyme deficiency, and genetic testing to identify the specific gene mutations causing the condition.
What is the difference between MPS IVA and MPS IVB?
The two types are caused by mutations in different genes that lead to different missing enzymes. Type A is caused by a GALNS gene mutation, while Type B is caused by a GLB1 gene mutation.
What does a 'Variant of Uncertain Significance' (VUS) mean on my lab report?
A VUS means a change was found in your DNA, but scientists are not yet sure if it causes the disease or is just a harmless natural variation. Your doctor may need to order additional genetic tests to see if this specific variant explains your symptoms.
Should my siblings get tested for MPS IV even if they have no symptoms?
Because MPS IV is a genetic condition, biological siblings of an affected person have a chance of being carriers or having the condition without showing symptoms yet. It is often recommended that siblings undergo genetic testing to understand their own health and carrier status.

Questions for Your Doctor

  • Does the diagnostic report show two 'pathogenic' variants, or is there a 'Variant of Uncertain Significance' (VUS)?
  • If a VUS was found, what further tests (like RNA analysis or bioinformatic studies) are needed to confirm it is causing the disease?
  • What was the 'residual activity' level of the GALNS (or GLB1) enzyme, and how does this relate to expected clinical severity?
  • Could biological siblings be carriers, and should they be tested even if they don't have symptoms?
  • If I plan to have children, what are the exact genetic risks, and can my partner be tested for carrier status?

Questions for You

  • Have biological family members been informed about the genetic nature of this diagnosis so they can pursue testing if desired?
  • When I look at the diagnostic report, can I locate the specific gene (GALNS or GLB1) and the two distinct mutations listed?
  • What symptoms (like changes in growth or gait) did I or my child experience first, and how do they match this biological diagnosis?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    A pictorial review of the radiographic skeletal findings in Morquio syndrome (mucopolysaccharidosis type IV).

    Padash S, Obaid H, Henderson RDE, et al.

    Pediatric radiology 2023; (53(5)):971-983 doi:10.1007/s00247-022-05585-3.

    PMID: 36627376
  2. 2

    Mucopolysaccharidosis IVA and glycosaminoglycans.

    Khan S, Alméciga-Díaz CJ, Sawamoto K, et al.

    Molecular genetics and metabolism 2017; (120(1-2)):78-95 doi:10.1016/j.ymgme.2016.11.007.

    PMID: 27979613
  3. 3

    Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

    Peracha H, Sawamoto K, Averill L, et al.

    Molecular genetics and metabolism 2018; (125(1-2)):18-37 doi:10.1016/j.ymgme.2018.05.004.

    PMID: 29779902
  4. 4

    Clinical and genetic spectrums of Mucopolysaccharidosis type IV in Duhok city, Kurdistan region, Iraq.

    Haleem AA

    Cellular and molecular biology (Noisy-le-Grand, France) 2025; (71(3)):42-47 doi:10.14715/cmb/2025.71.3.5.

    PMID: 40235322
  5. 5

    [Morquio disease (Mucopolysaccharidosis type IV-A): clinical aspects, diagnosis and new treatment with enzyme replacement therapy].

    Politei J, Schenone AB, Guelbert N, et al.

    Archivos argentinos de pediatria 2015; (113(4)):359-64.

    PMID: 26172013
  6. 6

    [Mucopolysaccharidosis: clinical features, diagnosis and management].

    Suarez-Guerrero JL, Gómez Higuera PJ, Arias Flórez JS, Contreras-García GA

    Revista chilena de pediatria 2016; (87(4)):295-304.

    PMID: 26613630
  7. 7

    Chondroitin sulfate disaccharide is a specific and sensitive biomarker for mucopolysaccharidosis type IVA.

    Chin SJ, Saville JT, McDermott BK, et al.

    JIMD reports 2020; (55(1)):68-74 doi:10.1002/jmd2.12132.

    PMID: 32905071
  8. 8

    Investigation of GALNS variants and genotype-phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA.

    Yi M, Wang Y, Gao X, et al.

    Journal of inherited metabolic disease 2022; (45(3)):593-604 doi:10.1002/jimd.12491.

    PMID: 35212421
  9. 9

    Early screening for respiratory and cardiac complications in pediatric mucopolysaccharidosis IVA: Insights from a case.

    Shu H, Shang X, Sun Y, et al.

    Intractable & rare diseases research 2025; (14(4)):303-305 doi:10.5582/irdr.2025.01053.

    PMID: 41341911
  10. 10

    Novel data on growth phenotype and causative genotypes in 29 patients with Morquio (Morquio-Brailsford) syndrome from Central-Eastern Europe.

    Jezela-Stanek A, Różdżyńska-Świątkowska A, Kulpanovich A, et al.

    Journal of applied genetics 2019; (60(2)):163-174 doi:10.1007/s13353-019-00491-1.

    PMID: 30927141
  11. 11

    Clinically relevant pseudoexons of the GALNS gene and their antisense-based correction.

    Bychkov I, Shchukina E, Zakharova E

    Molecular medicine (Cambridge, Mass.) 2025; (31(1)):196 doi:10.1186/s10020-025-01243-0.

    PMID: 40382551
  12. 12

    A Novel, Possibly Pathogenic, COL4A1 Gene Variant (c.3698G>A) in a Family With Childhood Epilepsy and Leukoencephalopathy.

    Gaini R, Denniss J, Lengel A, Lackey EA

    Cureus 2023; (15(11)):e48553 doi:10.7759/cureus.48553.

    PMID: 38074064
  13. 13

    Molecular characterization of mucopolysaccharidosis type IVA patients in the Andean region of Colombia.

    Pachajoa H, Acosta MA, Alméciga-Díaz CJ, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2021; (187(3)):388-395 doi:10.1002/ajmg.c.31936.

    PMID: 34542925
  14. 14

    Example of Intrafamilial Clinical Polymorphism in a Family with Osteogenesis Imperfecta.

    Galkina VA, Vasilyeva TA, Tebieva IS, et al.

    Genes 2025; (16(5)) doi:10.3390/genes16050475.

    PMID: 40428297

This page explains the biology and diagnostic testing for MPS IV for educational purposes only. Always consult a genetic counselor or your medical team to interpret your specific genetic and enzyme test results.

Stay up to date

Get notified when new research about Mucopolysaccharidosis type 4 is published.

No spam. Unsubscribe anytime.